Xoma Royalty shares demonstrated positive momentum at the week’s opening, trading at $32.14 and marking a nearly 1 percent gain. This upward movement follows the company’s successful acquisition of LAVA Therapeutics, a strategic move that significantly enhances its portfolio. The transaction brings economic interests in two promising cancer therapeutics, developed in collaboration with industry leaders Johnson & Johnson and Pfizer.
Acquisition Terms and Portfolio Enhancement
Finalized on November 21, the acquisition agreement stipulates that LAVA Therapeutics shareholders will receive $1.04 per share. Additionally, they will obtain a non-transferable Contingent Value Right (CVR). These CVRs entitle holders to 75% of the net proceeds generated from LAVA’s existing partner-related business and its company-controlled programs. A potential extra payment of up to $0.23 per CVR is also possible, contingent upon the final resolution of certain potential liabilities.
Chief Executive Officer Owen Hughes highlighted the value-creating potential of the newly acquired programs, stating they “have the potential to create significant value for the LAVA CVR holders and Xoma Royalty.” Following the acquisition of approximately 91.1% of LAVA’s outstanding shares, trading of LAVA stock on the Nasdaq was suspended.
Should investors sell immediately? Or is it worth buying Xoma?
Expanding Influence Through Strategic Moves
This acquisition is part of a broader, active strategy by Xoma to expand its market presence. Just days prior, on November 19, the company acted in an advisory capacity for XenoTherapeutics’ purchase of Repare Therapeutics. This series of strategic transactions underscores Xoma’s multifaceted approach to increasing its industry influence and generating shareholder value.
The current trading range for Xoma stock, between $18.35 and $39.92, reflects a period of significant growth and strategic repositioning. Market observers are now questioning whether the company can maintain its aggressive acquisition strategy to solidify this upward trajectory.
Ad
Xoma Stock: Buy or Sell?! New Xoma Analysis from January 10 delivers the answer:
The latest Xoma figures speak for themselves: Urgent action needed for Xoma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 10.
Xoma: Buy or sell? Read more here...
